Antibody response to pneumococcal polysaccharide conjugate vaccine using diphtheria toxoid as carrier in mice
10.3760/cma.j.cn112309-20241115-00391
- VernacularTitle:基于白喉类毒素载体的肺炎球菌多糖结合疫苗诱导小鼠抗体水平应答研究
- Author:
Zhe LI
1
;
Baosong LI
;
Xuexue ZHENG
;
Zhe CHAO
;
Yan WU
;
Guoxia DONG
;
Yajun TAN
;
Xiao MA
Author Information
1. 中国食品药品检定研究院百白破疫苗和毒素室，国家卫生健康委员会生物技术产品检定方法及其标准化重点实验室，国家药品监督管理局生物制品质量研究与评价重点实验室，北京 102629
- Publication Type:Journal Article
- Keywords:
Diphtheria toxoid;
DTaP vaccine;
Pneumococcal conjugate vaccine;
Antibody;
Potency
- From:
Chinese Journal of Microbiology and Immunology
2025;45(9):768-772
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the levels of diphtheria-specific binding antibodies and neutralizing antibodies in mice immunized with pneumococcal polysaccharide conjugate vaccine using diphtheria toxoid as a carrier.Methods:NIH mice were immunized with one batch of diphtheria, tetanus and acellular pertussis combined vaccine, absorbed (DTaP-1) or three different batches of 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13, containing diphtheria toxoid vector) at three dilutions (5-, 10- and 20-fold dilution). Serum samples were collected to test for diphtheria-specific antibody titers and diphtheria potencies of the vaccines. Another three batches of DTaP vaccine and three batches of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis combined vaccine (Tdap) were used to immunize NIH mice. Serum samples were collected and the diphtheria potencies were detected. Statistical analysis was performed using one-way analysis of variance.Results:At the 5-fold and 10-fold dilutions, the titers of diphtheria-specific antibodies induced by three batches of PCV13 vaccine were all lower than those by DTaP-1 vaccine (all P<0.001), while there was no statistically significant difference at the 20-fold dilution ( P>0.05). The diphtheria potencies of the DTaP-1 vaccine and the three batches of PCV13 vaccine were 100.5, 76.2, 64.5, and 62.0 IU/ml, respectively. The diphtheria potencies of another three batches of DTaP vaccine were 82.5, 83.6, and 79.9 IU/ml, respectively, and those of three batches of Tdap vaccine were 10.3, 12.2, and 12.9 IU/ml, respectively. There was no statistically significant difference in diphtheria potency between DTaP vaccine and PCV13 vaccine( P>0.05), while there was a statistically significant difference between Tdap vaccine and the PCV13 vaccine ( P<0.001). Conclusions:The pneumococcal polysaccharide conjugate vaccine with diphtheria toxoid has good diphtheria immunogenicity and can induce the production of higher levels of diphtheria-specific binding antibodies and protective neutralizing antibodies in vivo. Pneumococcal capsular polysaccharide exerts an immune enhancement effect on diphtheria toxoid. The relevant results provide valuable guidance for determining carrier protein dosage in bacterial polysaccharide conjugate vaccines, planning vaccine co-administration, and selecting the dosage of diphtheria toxoid antigen in the research and development of combined vaccines.
